TRIARYL COMPOUNDS FOR TREATING PD-L1 DISEASES Russian patent published in 2025 - IPC C07D247/02 C07C25/02 C07C25/24 A61K31/03 A61K31/505 A61K31/513 

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention relates to a compound of general formula (Ia) or a pharmaceutically acceptable salt thereof, where: R^1a, R^1b, R^1c, and R^1d each independently selected from a group consisting of H, halogen, and C_1-3 alkoxy group; X¹ is C_1-3 alkylene, optionally substituted with one C_1-2 alkyl; R^2a and R^2b each independently selected from a group consisting of H, C_1-8 alkyl, -Y, -X²-C(O)₂R^a, -X²-OR^a, -X²-NR^aR^b, -X²-CONR^aR^b, -X²-SO₃R^a, and -X²-Y, where each X² is C_1-6 alkylene, any C_1-8 alkyl or C_1-6 alkylene is optionally further substituted with one or two substituents independently selected from OH and CO₂H, and each Y is selected from the group consisting of C_3-6 cycloalkyl, C_4-8 heterocyclyl, containing 1–3 heteroatoms independently selected from N and O, and 5–6 membered heteroaryl containing two N heteroatoms, each of which is optionally further substituted with 1–4 substituents independently selected from the group consisting of an oxo group, OH, C_1-4 alkyl, C_1-4 alkoxy group and CONH₂; or R^2a and R^2b are combined to form 4–10 membered ring or spirocyclic ring, optionally having one or two additional ring members selected from O and N; where ring or spirocyclic ring formed during combination R^2a and R^2b, is substituted with 0–4 substituents independently selected from the group consisting of oxo group, C_1-8 alkyl, -X³-C(O)₂R^a, -X³-OR^a, and -X³-NR^aR^b, where X³ is a bond or C_1-6 alkylene; R³ and R⁴ each independently selected from a group consisting of F, Cl, CN, and CH₃; A is selected from a group consisting of -N(R^a)-, and -C(=O)N(R^a)-; Z is selected from the group consisting of structures i), ii) and iii), specified in the claims; where if A is -N(R^a)-, then Z is condensed bicyclic 9- or 10-member heteroaryl ring containing 1–4 heteroatoms independently selected from N, O and S, optionally substituted with 1–3 substituents R^c; each R^a is independently selected from a group consisting of H, C_1-6 alkyl, C_1-6 hydroxyalkyl, and C_1-6 alkylene-CO₂H; each R^b is independently selected from a group consisting of H, C_1-6 alkyl, C_1-6 hydroxyalkyl, and C_1-6 alkylene-CO₂H, each of which is optionally further substituted with one or two substituents independently selected from OH, CONH₂, and CO₂H; and each R^c is independently selected from a group consisting of H, halogen, C_1-6 alkyl, -X⁴-C(O)₂R^a, -O-X⁴-C(O)₂R^a, -X⁴-OR^a, -X⁴-NR^aR^b, -X⁴-CONR^aR^b, and -O-X⁴-CONR^aR^b, where each X⁴ is a bond or C_1-6 alkylene. Invention also relates to an individual compound selected from a group of compounds given in the formula of invention and a method of treating an individual suffering from or susceptible to a disease or disorder involving the PD-1 signalling pathway.

EFFECT: compounds for treating diseases or disorders associated with PD-1 signalling pathway.

26 cl, 209 ex, 2 tbl

(Ia)